Tirzepatide is a dual GIP and GLP-1 receptor agonist administered via weekly subcutaneous injection. It is an FDA-approved prescription medication indicated for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound). This potent compound works by enhancing insulin sensitivity, slowing gastric emptying, and reducing appetite to support metabolic health.
| Weight | 30mg, 60mg |
|---|
Dual Mechanism: Activates both GIP and GLP-1 hormone receptors.
Indications: Approved for Type 2 Diabetes and chronic weight management.
Administration: Once-weekly subcutaneous injection using a single-dose pen.
Effectiveness: Demonstrated significant weight reduction in clinical trials (SURMOUNT-1).
This website contains information about supplementary products. By entering, you confirm that you are of legal age (18 years or older) to access this information. If you are not of legal age, please leave this site immediately.
